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The organic nitrates came into use in the therapy of
cardiovascular disease well over a century ago. At that time,
and for decades thereafter, they were administered acutely
to relieve symptoms of myocardial ischemia and pulmonary
congestion. With the later introduction of long-acting
preparations in an effort to prevent symptoms of ischemia
and/or left ventricular dysfunction, the problem of tolerance
during continuous dosing was soon documented. There has
since been a tremendous focus of investigation concerning
the etiology of tolerance and methods to prevent it.
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In the mid 1990s it was reported that therapy with
nitroglycerin was associated with increased free radical
production by the endothelium and that this biochemical
response appeared to play an important role in the
development of tolerance (1). This observation, the “free
radical hypothesis” of the etiology of tolerance, was
followed by a rapid increase in our understanding of the
impact of organic nitrates on both vascular biochemistry
and vascular function. Animal models of nitrate exposure
have now documented that sustained exposure to organic
nitrates, particularly glyceryl trinitrate (GTN), is associ-
ated with: 1) increased superoxide anion production, with
this increase apparently arising from a number of enzy-
matic sources (1–3); 2) increased tissue content of
endothelin-1, possibly mediated by increased production
of angiotensin II (4); 3) activation of protein kinase C
(4); 4) development of abnormalities in L-arginine trans-
port with subsequent abnormalities in endothelial nitric
oxide synthase function (5,6); and 5) abnormalities in the
function of mitochondrial aldehyde dehydrogenase (7).
At the same time, human experimentation has docu-
mented that sustained therapy with GTN is associated
with an increase in the vascular sensitivity to vasocon-
striction (8) and evidence of abnormal responses to
endothelium-dependent vasodilation in a number of
vascular beds (9,10). It should be emphasized that most
experimental work to date has involved GTN, with little
information published concerning the impact of other
organic nitrates. Some observations have suggested that
there may be important differences between different
organic nitrates. For example, it has been suggested that
pentaerythritol tetranitrate does not appear to cause
increased free radical production (11) and that this
characteristic is associated with less evidence of hemody-
namic tolerance (12) as well as improved endothelium-
dependent vasomotor responses during sustained therapy
(13).
In this issue of the Journal, Hink et al. (14) from Thomas
Mu¨nzel’s laboratory, provide more data concerning the far-
reaching biochemical effects of nitroglycerin therapy on vascu-
lar biochemical homeostasis. Their observations document that
relatively short-term continuous GTN therapy in both rats and
rabbits was associated with the development of important
abnormalities in the function of prostacyclin synthase (PGI2-
S), the enzyme responsible for the synthesis of prostaglandin-
I2, a compound with potent vasodilatory and antiplatelet
effects. Their observations serve to remind us that some of the
acute vasomotor effects of nitrates are mediated through the
stimulatory effects of either GTN and/or the active metabolite
nitric oxide on PGI2 production (15). More importantly, they
identify yet another apparent adverse effect of sustained GTN
therapy on vascular homeostasis and function. Their data
document that sustained GTN therapy is associated with a
marked decrease in PGI2-S activity, with subsequent reduction
in PGI2 production. The inhibitory effect of GTN exposure on
PGI2-S function appears to be mediated by increased tyrosine
nitration of PGI2-S, a reflection of increased peroxynitrite
formation, which is demonstrated to occur during sustained
nitrate exposure.
What is not addressed in the current publication is the
relative importance of the oxidative damage to PGI2-S in
the development of nitrate tolerance and the abnormal-
ities of vascular function observed in vivo during nitrate
therapy. During the past several years, a number of
important cellular enzyme systems have been shown to
develop impaired function in response to sustained ther-
apy with GTN, including membrane-bound oxidases
(16), endothelial nitric oxide synthase (3,17), arginine
transporters (6) and, most recently, mitochondrial alde-
hyde dehydrogenase (7). In each case, these abnormalities
appear to result in or be caused by increased bioavailabil-
ity of superoxide anion and related reactive oxygen
species. Unfortunately, the relative importance of these
functional abnormalities remains uncertain. Indeed, it
remains unclear which, if any, of the observed changes are
primary events versus secondary phenomena related to
the increase in radical production caused by the nitrate.
Directly relevant to this question is the fact that the
fundamental mechanism that triggers the increase in
superoxide anion production remains unknown. It has
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been suggested that this may result directly from the
biotransformation and denitrification of GTN (and, po-
tentially, other organic nitrates) (18); however, there has
been no definitive documentation of this process. Further
understanding of the fundamental mechanisms involved
is required before the exact cascade of events will be
unraveled and the relative importance of these multiple
observed biochemical abnormalities determined.
Despite these factual uncertainties, the potential impli-
cations of these findings are intriguing. The data provided
by Hink et al. (14) suggest that sustained GTN therapy is
associated with a decrease in production of PGI2, with the
subsequent loss of important vasodilator and antiplatelet
effects. Furthermore, it is possible that inhibition of PGI2-S,
with a consequent increase in the concentration of
prostaglandin-H2, may also be associated with an increase
in the synthesis of thromboxane-A2, with its potent vaso-
constrictor and platelet activation effects. However, the
majority of patients with coronary artery disease are pre-
scribed the cyclooxygenase inhibitor acetylsalicylic acid,
which reduces the production of many prostaglandins,
including both PGI2 and thromboxane-A2. The dose de-
pendency of the inhibitory effect of acetylsalicylic acid on
platelet and vascular prostaglandin production and the
relevance of this to the beneficial effects of acetylsalicylic
acid in the therapy of coronary artery disease has been
debated for decades (19). In light of these factors, it cannot
be concluded with certainty that the inhibitory effect of
GTN on PGI2-S is necessarily associated with adverse
effects on clinical outcome. Nevertheless, the authors
correctly point out that this combination of effects,
particularly when combined with the inhibitory effect of
GTN on endothelial nitric oxide function, sets a stage
where GTN therapy is associated an inhibition of the
production the two most important endogenous vasodi-
lator, antithrombotic and antiproliferative signaling
pathways in vascular tissue.
There is growing evidence that sustained nitrate therapy,
particularly with GTN, is associated with a multitude of
adverse effects on vascular biochemistry and function. Some
five years ago, our group noted that some of the vascular
changes observed during sustained nitrate therapy were
potentially atherogenic (20). Despite these concerns, we still
have almost no information concerning the impact of
chronic nitrate therapy on long-term clinical outcomes.
Trials of the organic nitrates in angina have been small with
short-term follow-up periods. Larger trials, in the postin-
farction setting, have used short follow-up periods and the
impact of nitrate therapy independent of hydralazine in the
setting of chronic heart failure remains ambiguous (21,22).
Interestingly, when retrospective analyses have been per-
formed examining the impact of nitrate therapy in the
postinfarct period, negative results have been observed (23).
These observations, when combined with the obvious neg-
ative impact of nitrate therapy on endothelial function,
should drive us to more carefully examine our chronic use of
these agents in patients with a variety of cardiovascular
diseases.
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